Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03380624 · ClinicalTrials.gov registry record · Phase 4
Tear Lipid Layer Thickness With Emollient Eye Drops
A Phase 4 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT03380624: Completed Phase 4 study, sponsored by Ohio State University.
NCT03380624 is a Phase 4 study that has completed, run by Ohio State University. The registered enrollment target is 21 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03380624, a Phase 4 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
Crossover comparison of lipid layer thickness with two artificial tear formulations
Primary Outcome
Change in tear lipid layer thickness
Interventions
- DRUG Refresh Optive MEGA-3
- DRUG Refresh Optive
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2018-06-30 |
| Phase | Phase 4 |
What the finished NCT03380624 record still lists
NCT03380624 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Refresh Optive MEGA-3 is the first listed.
NCT03380624 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03380624 about?
NCT03380624 is a clinical study titled "Tear Lipid Layer Thickness With Emollient Eye Drops". Crossover comparison of lipid layer thickness with two artificial tear formulations
What is the current status of trial NCT03380624?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2017-03-01. Estimated completion is 2018-06-30.
What interventions are being tested in trial NCT03380624?
The interventions under investigation include: Refresh Optive MEGA-3 (DRUG), Refresh Optive (DRUG).
Who is sponsoring clinical trial NCT03380624?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03380624's enrollment target sits among peer trials
21 1742nd of 2000 higher than 248 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI